Following the completion of the Series A round financing in January 2021, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharma") has recently completed the Series B and B+ financing. Led by Efung Investment Management, followed by Acer Capital, Lianrun Oriental, Hainan Jinbei and other investors, the total amount of this round of financing is nearly 100 million of RMB.

With this round of financing, Beimei will be committed to invest more in the self-development pipeline, establishment of the new R&D center and pilot production facility, the research and development of new drugs in special pediatric dosage forms, in-licensing of new products from the domestic and overseas, and team expansion, etc. In addition, Beimei will accelerate the establishment of new technology platforms such as taste masking and precise dosing to further enhance the R&D strength of the company.

Beimei Pharma focuses on the pediatric prescription medicines to meet the clinical needs for children. With various proprietary technology platforms, Beimei develops and license-in high-quality prescription drugs for children, aiming to become the leading enterprise in the field of pediatric drugs in China.

Wu Guangmei, CEO of Beimei Pharma, said, “This round of financing will further accelerate Beimei's R&D capabilities and drive the in-licensing of pediatric products. We are very grateful for the recognition for Beimei Pharma by the top industrial investment institutions. Together with our investors, we hope to witness Beimei continues to develop and bring high quality, full range, safe and effective pediatric drugs that will ultimately benefit Chinese children, in basis of its forward-looking product layout and years of accumulation in pediatric drugs, as well as the high-level pediatric drug development proprietary technology platforms.”

Zhu Pai, Managing Partner of Efung, said, “At present, Chinese children's drugs are under the situation with limited specialized varieties and low development interests. Beimei Pharma, with its focuses on the research and development of pediatric drug, has a first-class R&D team, continuous innovation capability and sound business layout, and an advanced pediatric drug R&D platform. The core product Oseltamivir Phosphate for Oral Suspension is the first one approved for 14 days for neonatal treatment of influenza. Efung continues to be value the layout of Beimei in the field of pediatric drugs, and expects Beimei to launch more products with self-owned intellectual property rights, growing into a unique pediatric drug leader in China.”

About Efung Capital

Shenzhen Efung Capital is one of the earliest venture capital institutions that specialized in biomedicine investment in China. Efung has a high-caliber management team and an experienced investment team, which consist of MDs/PhDs graduated from top domestic and international institutions. It focuses on medical and healthcare sectors, especially in VC and PE investment in global biopharmaceuticals. Throughout these years, Efung has explored profoundly, and has invested domestic and oversea high-quality enterprises including Chipscreen Bioscience, Frontier Biotech, Ascentage Pharma, Lifotronic Technology, Harbour Biomed, OBiO Technology, Asieris Pharmaceuticals, 3D Medicines, Apexigen and Centrexion et al.. Efung Capital has demonstrated a solid track record, and has achieved strong revenue and earnings growth. It was honored with “Zero2IPO Group2020 Best Healthcare Investment Institution TOP30”, “ChinaVenture 2019 Best Exit Cases TOP10”and “The Most Dynamic Pharmaceutical VC Institutions in China”, and has also been elected as “Shenzhen TOP10 VC Institutions” for several consecutive years.

About Acer Capital

Acer Capital Investment Management Co., Ltd. is a private equity investment institution established in 2019 by financial and industry experts with more than 10 years of experience. It is located in Shenzhen and has branches in Shanghai and Hangzhou. Acer Capital focuses on investment in hard technology and biomedical fields, adheres to the values of "industrial precipitation and value mining," and strives to explore and cultivate high-quality enterprises, creating long-term value for enterprises and fund investors.

About Lianrun Oriental

Lianrun Dongfang is a integrated equity investment platform initiated and founded by the partners of well-known institutions such as Chuangxintou, Leaguer Angel, Flash Stone Consulting and other listed companies, with 20-years traceable investment performance. Lianrun Oriental focuses on in-depth research and layout of vertical industry in several core fields such as intelligent manufacturing, TMT, biomedicine and enterprise-level service, and dedicated to explore the leaders with technological barriers in different segmentations.

About Beimei Pharma

Beimei Pharmaceuticals focuses on the field of pediatric prescription medicines in China, aiming to become a novel pharmaceutical enterprise integrating research and development, licensing in, production, and sales. Beimei takes in-house research and development and international licensing-in as its strategic direction. At present, the product pipeline covers the respiratory system, anti-infection, nervous system, digestive system, and other fields. Beimei is committed to providing convenient, accurate, excellent-tasted and high-quality products for Chinese pediatric patients.